Physician profile
Zach E Amdurer
NPI 1679008940
$5,034.04
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.28 · 2021: $3,204 · 2022: $1,457 · 2023: $186 · 2024: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $285 · Education: $45.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $285.27 |
| Education | $45.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $925.44 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $803.74 | 2021-2024 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.04 | 2021-2022 | |
| Lilly USA, LLC | $279.59 | 2021-2022 | |
| Medtronic, INC. | $239.44 | 2021-2022 | |
| Pfizer INC. | $236.01 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $193.19 | 2021-2022 | |
| Glaxosmithkline, LLC. | $173.61 | 2021-2022 | |
| Amgen INC. | $161.57 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $155.29 | 2021-2023 | Xarelto |
| Novo Nordisk INC | $132.13 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $129.15 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $123.92 | 2021 | |
| Amarin Pharma, INC. | $122.65 | 2019-2021 | |
| Horizon Therapeutics Plc | $96.00 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zach Amdurer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.